Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 1,743 trials

B-Cell Malignancies: SRG-1505 Treatment Study

We are testing a new treatment called SRG-1505 for individuals with mature B-cell malignancies. This study aims to evaluate its safety and appropriate dosage.

B-Cell Neoplasms and Lymphomas>2 yearsSafety phase (I)HematologyOncology

Colon Cancer Treatment: Neo-Adjuvant Chemotherapy for Seniors

We are studying whether a 6-week chemotherapy treatment before surgery helps older adults with resectable colon cancer live longer and stay disease-free. This trial aims to personalize treatment for patients aged 70 and older.

Colon Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Type 1 Diabetes: New Cell Therapy for Children

We are studying a new treatment combining cell therapy and an antibody for children with early-stage type 1 diabetes. The goal is to see if this approach can help delay the onset of diabetes symptoms.

Prediabetes>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesEndocrinologyInfectious DiseasesPediatrics

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia

We are comparing a new treatment, bomedemstat, to hydroxyurea in people with essential thrombocythemia who haven't been treated before. The goal is to see which treatment better reduces symptoms and fatigue.

Essential Thrombocythemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHematology

Autism Spectrum Disorder: Sensorimotor Therapy and Oxytocin

We are exploring whether a new therapy combined with a single dose of oxytocin can improve social connections in children with autism. The goal is to see if this approach enhances their interactions with others.

Autism Spectrum Disorder>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPsychiatry

Osteoarthritis in the Thumb: Comparing Treatments

We are studying whether steroid injections are more effective than saline injections and occupational therapy for painful thumb osteoarthritis. The goal is to improve pain, function, and overall quality of life.

Osteoarthritis of the Thumb>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and TraumatologyRheumatology

Advanced Solid Tumors: XON7 Antibody Study

We are investigating a new antibody treatment for patients with advanced or metastatic solid tumors. This study aims to evaluate its safety and how well it works in treating these cancers.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Glioblastoma Treatment: Lomustine with or without Reirradiation

We are studying whether adding a second round of radiation to lomustine improves survival and quality of life for patients with recurrent glioblastoma. This trial aims to find out if this combination is more effective than lomustine alone.

Glioblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Brain Injury: Effects of Ketamine Treatment

We are studying whether adding ketamine to treatment helps lower the intensity of care needed for patients with acute brain injuries. We also want to see if it affects intracranial pressure.

Traumatic Brain Injury>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Advanced Solid Tumors: STAR0602 Treatment

We are testing a new drug, STAR0602, to see if it can help stimulate the immune system in patients with advanced solid tumors that cannot be surgically removed. This study aims to explore its effects on tumors that have spread locally or to other parts of the body.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

TOS-358 for Adults with Solid Tumors

We are testing a new treatment called TOS-358 in adults with solid tumors. This study aims to understand how safe it is and how well it works.

Malignant Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Influenza Vaccine Study for Hematological Cancer Patients

We are testing whether a high-dose flu vaccine works better than a standard dose in patients with hematological cancers. This study aims to improve vaccine effectiveness and understand immune responses in these patients.

Hematological Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInfectious Diseases

Advanced Solid Tumors: JNJ-87890387

We are testing a new treatment called JNJ-87890387 for patients with advanced solid tumors. The goal is to understand its safety and how it works in the body.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Cancer Treatment: Immune Markers and Side Effects

We are exploring blood markers in cancer patients to identify signs of side effects from checkpoint inhibitor treatments. This research may help improve safety and management of these therapies.

Solid Tumor>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Influenza Vaccine After Heart Attack: ELIMINATE Trial

We are studying whether an influenza vaccine can help reduce heart inflammation in people who have had a heart attack. This trial compares the vaccine to a placebo to see its effects on heart health.

Heart Attack>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCardiologyInfectious Diseases

Stomach Cancer: MK-2870 Treatment Study

We are comparing a new treatment called MK-2870 to standard care for people with advanced stomach cancer. The goal is to see if MK-2870 can improve survival and manage symptoms better.

Adenocarcinoma of the Gastroesophageal Junction>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementGastroenterologyOncology